Abstracts tagged "Biomarkers"

Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting
Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Alexandra Friedman¹, Nicholas Young², Paul Jensen³, Xiaolin Zhang⁴, Wael N. Jarjour⁵, Brad H. Rovin⁴, Daniel Birmingham³, Lee Hebert³ and Stacy P. Ardoin⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ³Medicine, Ohio State University Medical Center, Columbus, OH, ⁴Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ⁵Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…
Abstract Number: 568 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Anthony Marotta¹, A. W van Kuijk², Walter P. Maksymowych³ and Paul Peter Tak⁴, ¹Augurex Life Sciences Corp, North Vancouver, BC, Canada, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: 14-3-3 eta is a synovial-derived biomarker whose serum expression is independently associated with joint damage in RA and PsA. We previously reported that 14-3-3…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…
Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting
Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover
Anne C. Bay-Jensen¹, Inger Byrjalsen², Andrew Kenwright³, Thierry Sornasse⁴, Claus Christiansen⁵ and Morten Asser Karsdal⁶, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Research & Development, Nordic Bioscience, Herlev, Denmark, ³Roche, Welwyn Garden City, United Kingdom, ⁴Genentech, South San Francisco, ⁵CCBR, Ballerup, Denmark, ⁶Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Masataka Kuwana¹, Tsutomu Takeuchi² and Junichi Kaburaki³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Med, Shinakasaka Clinic, Tokyo, MI, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…
Abstract Number: 430 • 2012 ACR/ARHP Annual Meeting
Comprehensive Microrna Analysis Identifies Mir-24, Mir-26a, and Mir-125a-5p As Plasma Biomarkers for Rheumatoid Arthritis
Koichi Murata¹, Moritoshi Furu², Hiroyuki Yoshitomi³, Masahiro Ishikawa¹, Hideyuki Shibuya¹, Hiromu Ito² and Shuichi Matsuda¹, ¹Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: MicroRNAs (miRNAs) are present in human plasma in a stable form despite the endogenous RNase activity. Plasma miRNAs are non-invasive biomarker for cancer detection…
Abstract Number: 2166 • 2012 ACR/ARHP Annual Meeting
Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Inger Byrjalsen³, Andrew Kenwright⁴, Adam Platt⁴, Thierry Sornasse⁵ and Claus Christiansen⁶, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Product Development Immunology, Genentech, Inc., South San Francisco, USA, San Fransisco, CA, ⁶CCBR, Ballerup, Denmark
Background/Purpose: RA is characterized by poly-articular synovial inflammation, cartilage loss and erosion of subchondral bone. It is critical to diagnose and effectively treat the disease…
Abstract Number: 1257 • 2012 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L
Yurilis Fuentes-Silva¹, Soham Al Snih², Natali Serra-Bonett¹, Juan De Sanctis³ and Martin A. Rodriguez⁴, ¹Rheumatology, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ²Division of Rehabilitation Sciences, Division of Geriatrics. Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX, ³Immunology, Instituto de Inmunología, Caracas, Venezuela, ⁴Centro Nacional de Enfermedades Reumáticas, Hospital Universitario de Caracas, Caracas, Venezuela
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, associated with an excess of cardiovascular morbidity and mortality due to accelerated atherosclerosis. The appearance of…
Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Arthur G. Pratt¹, Philip M. Brown², Simon J. Cockell³, Gillian Wilson⁴ and John D. Isaacs¹, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom, ³Bioinformatics Unit, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Directorate of Musculoskeletal Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…
Abstract Number: 407 • 2012 ACR/ARHP Annual Meeting
The I50V IL4R SNP Is Associated with Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis
Jan Leipe¹, Iryna Prots², Markus A. Schramm¹, Matthias Witt¹, Axel P. Nigg¹, Christiane S. Reindl¹, Claudia Dechant¹, Mathias Grunke¹, Hendrik Schulze-Koops¹ and Alla Skapenko³, ¹Division of Rheumatology and Clinical Immunology, Med. Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg, Junior Research Group III, Interdisciplinary Center for Clinical Research Nikolaus-Fiebiger Center for Molecular Medicine, Erlangen, ³Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: A single nucleotide polymorphism (SNP) in the IL4R gene (I50V, rs 1805010) has previously been associated with an aggressive destructive course of rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.